CN101121748A - 抗传染性法氏囊病病毒vp4蛋白单克隆抗体 - Google Patents
抗传染性法氏囊病病毒vp4蛋白单克隆抗体 Download PDFInfo
- Publication number
- CN101121748A CN101121748A CNA2007100701317A CN200710070131A CN101121748A CN 101121748 A CN101121748 A CN 101121748A CN A2007100701317 A CNA2007100701317 A CN A2007100701317A CN 200710070131 A CN200710070131 A CN 200710070131A CN 101121748 A CN101121748 A CN 101121748A
- Authority
- CN
- China
- Prior art keywords
- ibdv
- protein
- monoclonal antibody
- recombinant protein
- disease virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 8
- 208000027312 Bursal disease Diseases 0.000 title claims abstract description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 26
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 101500001537 Avian infectious bursal disease virus Protease VP4 Proteins 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 19
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 19
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims abstract description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004202 carbamide Substances 0.000 claims abstract description 10
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 6
- 229910052759 nickel Inorganic materials 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 210000003000 inclusion body Anatomy 0.000 claims description 4
- 241000702626 Infectious bursal disease virus Species 0.000 abstract description 24
- 206010003445 Ascites Diseases 0.000 abstract description 11
- 238000002965 ELISA Methods 0.000 abstract description 10
- 238000010790 dilution Methods 0.000 abstract description 9
- 239000012895 dilution Substances 0.000 abstract description 9
- 238000010367 cloning Methods 0.000 abstract description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 4
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 abstract description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 230000007910 cell fusion Effects 0.000 abstract 1
- 230000009920 chelation Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 210000004989 spleen cell Anatomy 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108010067390 Viral Proteins Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 230000024835 cytogamy Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 101710081079 Minor spike protein H Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241001533426 Avibirnavirus Species 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910001453 nickel ion Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 101800000955 Structural peptide 1 Proteins 0.000 description 1
- 101800000956 Structural peptide 2 Proteins 0.000 description 1
- 101800000957 Structural peptide 3 Proteins 0.000 description 1
- 101800000936 Structural peptide 4 Proteins 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000631 analytical pyrolysis Methods 0.000 description 1
- 238000009361 aviculture Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明抗传染性法氏囊病病毒(IBDV)VP4蛋白单克隆抗体属于生物技术领域,涉及基因工程。将IBDV VP4基因克隆于原核表达载体pET-28a,在大肠杆菌BL21(DE3)中诱导表达;分离包涵体,用8M尿素溶解,经镍螯合亲和层析纯化获得VP4重组蛋白。用VP4重组蛋白免疫BALB/c小鼠,取其脾细胞与骨髓瘤细胞SP2/0进行细胞融合,以HAT培养基选择性培养后,以VP4重组蛋白和IBDV感染细胞进行双重ELISA筛选和有限稀释法克隆化,获得分泌抗IBDV VP4蛋白单克隆抗体的杂交瘤细胞株,其中4C3、6A4和6H8腹水的ELISA效价分别为:6.4×105、2.6×106和5.2×106,均能特异识别IBDV感染细胞的病毒蛋白,其Ig亚型重链为IgG1,轻链为κ。
Description
技术领域
本发明属于生物技术领域,涉及抗体工程技术,具体为抗传染性法氏囊病病毒VP4蛋白单克隆抗体。
背景技术
传染性法氏囊病病毒(infectious bursal disease virus,IBDV)是传染性法氏囊病(IBD)的病原,主要侵害3-6周龄雏鸡的法氏囊中枢免疫器官,破坏表面带有sIgM的B淋巴细胞,并引起脾脏、胸腺及外周血液淋巴细胞的凋亡,导致以淋巴细胞衰竭、坏死为主要特征的免疫缺陷性和免疫抑制性疾病。该病发病率高,病程短,除疾病自身可造成机体损伤外,还可导致多种疫苗免疫失败,严重危害养禽业的健康发展。IBDV属双RNA病毒科(Birnaviridae)禽双RNA病毒属(Avibirnavirus),无囊膜,具有单层衣壳,呈20面体立体对称,病毒基因组由双链双节段RNA组成,大节段A全长3259个核苷酸,含有两个部分重叠的开放阅读框架(ORF),大ORF全长共3036个核苷酸,按NH2-VP2-VP4-VP3-COOH的顺序编码分子量为110kDa的多聚前体蛋白(VP2/4/3),并剪切加工成为VP2蛋白前体(pVP2)、VP3和VP4蛋白,pVP2进一步加工成为成熟的VP2蛋白和4条多肽(pep46、pep7a、pep7b和pep11);小ORF全长共435-447个核苷酸,编码VP5非结构蛋白。小节段B全长2827个核苷酸,只有一个ORF编码VP1蛋白。
VP4由243个氨基酸组成,分子量约为28kDa,属于丝氨酸蛋白酶,具有水解蛋白活性,主要作用是对多聚前体蛋白VP2/4/3进行自我水解,使之水解成为pVP2、VP3和VP4三种病毒蛋白,其中pVP2-VP4和VP4-VP3确切剪切位点分别定位于L512A↓A513和M755A↓A756。此外,VP4还能激活VP1的合成,与病毒在感染细胞后形成的微管状结构有关,有可能也参与了病毒组装,但不诱导凋亡。由于IBDV病毒粒子不存在VP4蛋白,无法获得自然状态下的VP4病毒蛋白,严重制约VP4蛋白特性和功能的研究,利用VP4重组蛋白制备特异性单克隆抗体可为VP4研究提供必要的试剂和技术手段,对探讨VP4蛋白在IBDV病毒粒子形成及其致病方面的作用具有重要意义。
发明内容
本发明的目的是提供抗IBDV VP4蛋白单克隆抗体。
本发明的单克隆抗体是用纯化的IBDV VP4重组蛋白为抗原,通过杂交瘤细胞方法获得的,能特异识别IBDV感染细胞病毒蛋白的单克隆抗体。IBDV VP4重组蛋白是将IBDV VP4基因克隆于原核表达载体pET-28a,在大肠杆菌BL21(DE3)中诱导表达,分离包涵体,用8M尿素溶解,经镍螯合亲和层析纯化获得的表达蛋白。
该单克隆抗体的具体制备方法如下:
1、根据IBDV VP4基因cDNA序列设计一对引物,通过PCR扩增得到全长VP4基因。将IBDV VP4基因克隆于原核表达载体pET-28a,在大肠杆菌BL21(DE3)中诱导表达IBDVVP4蛋白;裂解表达菌体,分离包涵体,用8M尿素溶液溶解表达蛋白,经镍螯合亲和层析纯化,获得IBDV VP4重组蛋白。
2、用IBDV VP4重组蛋白免疫BALB/c小鼠,取其脾细胞与骨髓瘤细胞SP2/0进行细胞融合,以HAT培养基选择性培养后,以VP4重组蛋白和IBDV感染细胞进行双重ELISA筛选和有限稀释法克隆化,获得分泌抗IBDV VP4蛋白单克隆抗体的杂交瘤细胞株;将杂交瘤细胞注入经降殖烷致敏的BALB/c小鼠诱生腹水,对获得抗IBDV VP4蛋白单克隆抗体特性进行鉴定。
3、以ELISA测定抗IBDVVP4蛋白单克隆抗体的腹水效价,间接免疫荧光鉴定抗IBDVVP4蛋白单克隆抗体与IBDV病毒蛋白的反应性和特异性,用单克隆抗体亚型测定试剂盒鉴定抗IBDV VP4蛋白单克隆抗体的Ig亚类。
本发明的优点是:(1)本发明提供的IBDV VP4重组蛋白制备方法简单,纯度高;(2)本发明提供抗IBDV VP4蛋白的单克隆抗体特异性强,制备方法简单;(3)抗IBDV VP4蛋白单克隆抗体可用于VP4蛋白的特性和功能研究。
附图说明
图1为IBDV VP4重组表达质粒pET28a-VP4的鉴定图,图中1是阴性对照,2是质粒pET28a-VP4的PCR产物,3是100bp DNA ladder。
图2为IBDV VP4表达蛋白的SDS-PAGE鉴定图,图中1是蛋白质Marker,2是BL21(DE3)/pET-28a诱导表达菌体,3是BL21(DE3)/pET28a-VP4诱导表达菌体。
图3为抗VP4蛋白单克隆抗体的IFA鉴定图,图中A和B分别是单克隆抗体6A4与IBDVNB株感染及正常鸡胚成纤维细胞(CEF)的反应结果,C和D分别是单克隆抗体6H8与IBDVNB株感染及正常CEF的反应结果,E和F分别是单克隆抗体4C3与IBDV NB株感染及正常CEF的反应结果。
具体实施方式
1、IBDV VP4重组蛋白的制备:根据IBDV NB株A节段核苷酸序列设计引物,PCR扩增IBDV VP4基因,将其克隆于原核表达载体pET-28a,转化大肠杆菌BL21(DE3),经IPTG诱导表达IBDV VP4蛋白;收集表达菌体,冻融3次后,离心分离包涵体,用8M尿素溶液溶解表达蛋白,经镍螯合亲和层析纯化,获得IBDV VP4重组蛋白。
2、抗IBDV VP4蛋白单克隆抗体的制备:用等量弗氏佐剂乳化纯化的VP4重组蛋白,免疫6-8周龄BALB/c小鼠,取其脾细胞与骨髓瘤细胞SP2/0在聚乙二醇作用下进行细胞融合,用HAT培养基进行选择性培养;以纯化的VP4重组蛋白和IBDV感染CEF裂解物为检测抗原,用双重ELISA方法对杂交瘤细胞培养上清进行筛选,阳性杂交瘤经连续5次有限稀释法克隆化,获得稳定分泌抗VP4蛋白单克隆抗体的杂交瘤细胞株;以降殖烷致敏BALB/c小鼠后,将杂交瘤细胞注入致敏小鼠腹腔诱生腹水,获得抗IBDVVP4蛋白单克隆抗体。
3、抗IBDV VP4蛋白单克隆抗体的特性鉴定:以纯化VP4重组蛋白为检测抗原用间接ELISA方法测定抗IBDV VP4蛋白单克隆抗体的腹水效价;以间接免疫荧光鉴定抗IBDV VP4蛋白单克隆抗体与IBDV病毒蛋白的反应性和特异性;用SBA公司ClonotypingTMSystem/HRP亚型测定试剂盒鉴定抗IBDV VP4蛋白单克隆抗体重链和轻链的Ig亚型。
实施例1IBDV VP4重组表达质粒的构建
根据IBDV NB株A节段核苷酸序列(EF517528.1)设计合成特异性引物,上游引物5’-CGTCGTCCATGGCCGACAAGGGGTACGAGGTAGTC-3’(下划线为NcoI位点),下游引物5’CGTCGTCTCGAGCATGGCAAGGTGGTACTGGCGTCC-3’((下划线为XhoI位点)。以PCR从IBDVA节段质粒中扩增IBDV VP4基因,引入NcoI/XhoI酶切位点,PCR产物经NcoI/XhoI双酶酶切消化后,连接到原核表达载体pET-28a的NcoI/XhoI位点间,转化大肠杆菌Top10,提取转化细菌的质粒,以PCR鉴定重组表达质粒(图1),经序列测定验证,获得IBDV VP4重组表达质粒pET28a-VP4。
实施例2IBDVVP4重组蛋白的表达与纯化
以氯化钙法将重组表达质粒pET28a-VP4转化大肠杆菌BL21(DE3),挑取阳性克隆接种LB液体培养基(含50μg/mL Kan),37℃250r/min振荡培养过夜,次日按1∶100的比例接种于含10mL新鲜LB培养基100mL锥形瓶中,37℃300r/min振荡培养,当0D600=0.6时,加入终浓度为1mM IPTG诱导表达2h,4℃12000r/min离心30sec,收集菌体,冻融三次,4℃12000r/min离心10min,SDS-PAGE分析裂解菌体的上清和沉淀,分析IBDV VP4蛋白的表达情况(图2)。加入5倍体积8M尿素溶解沉淀,振荡至溶液澄清,4℃12000r/min离心10min,弃沉淀,上清转移至镍离子亲和层析柱中,振荡1h,使带有His标签的VP4表达蛋白与镍离子鳌合,先后用2倍柱床体积pH=8.0的8M尿素溶液,3倍柱床体积pH=6.3的8M尿素,3倍柱床体积pH=5.9的8M尿素和5倍柱床体积pH=4.5的8M尿素洗脱柱床,收集洗脱液1ml/管;用SDS-PAGE分析洗脱液,获得高纯度的VP4重组蛋白。
实施例3小鼠免疫
分别将纯化的IBDV VP4重组蛋白与弗氏佐剂等比例混合,充分乳化,制备VP4免疫抗原,免疫6-8周龄BALB/c纯系小鼠10只。首免以弗氏完全佐剂免疫抗原,背部皮下、皮内多点注射,每只100μg(0.2mL);间隔20天,用弗氏不完全佐剂免疫抗原进行第二次免疫,腹腔注射,每只100μg(0.2mL);间隔20天,用不加佐剂的VP4免疫抗原进行三免,肌肉注射,每只100μg(0.2mL);免疫15天后,尾静脉采血,以VP4重组蛋白为检测抗原,用间接ELISA方法测定免疫小鼠血清的抗体水平,免疫小鼠抗体滴度达到1∶4000以上,表明小鼠获得良好免疫效果。
实施例3杂交瘤细胞株的建立
1、细胞融合
细胞融合前3天,进行超强免疫,以不加佐剂的VP4重组蛋白尾静脉注射小鼠,每只50μg(0.1mL)。免疫小鼠经眼眶放血,收集血清,拉颈致死后,无菌取小鼠脾脏,分离脾细胞,经台盼兰染色计数,按5∶1的比例与SP2/0骨髓瘤细胞(2×107)混合,在PEG4000作用下进行细胞融合;融合细胞经洗涤后,用HAT选择培养基重悬,置5%CO2 37℃进行选择性培养,5天后半量换液,10天后改为HT培养基。待细胞克隆长至1/5-1/2培养孔时,吸取细胞培养上清检测分泌抗体。
2、杂交瘤细胞筛选
分别用纯化的VP4重组蛋白和IBDV感染CEF裂解物作为检测抗原,对杂交瘤细胞培养上清中的分泌抗体进行双重ELISA检测,筛选阳性杂交瘤细胞。用0.05M碳酸盐包被缓冲液(pH9.6)稀释纯化的VP4重组蛋白或IBDV感染CEF裂解物,加入酶标板,100μL/孔,37℃包被1h后转入4℃包被过夜;用含0.05%吐温20的PBS缓冲液(PBST)洗涤3次,加5%脱脂奶粉37℃封闭1h,每孔加入杂交瘤细胞培养上清100μL,37℃孵育2h;PBST洗3次,加入1∶5000倍稀释的辣根过氧化物酶(HRP)标记羊抗小鼠IgG抗体,37℃孵育1h,PBST洗4次,加入显色底物OPD-H2O2,避光反应10min后,用2MH2SO4终止反应,用酶标仪读取OD490值,以与阴性OD490值的比值大于2.1判为阳性。VP4重组蛋白和IBDV感染细胞两种抗原检测均呈阳性的杂交瘤细胞孔为阳性克隆。
3、有限稀释法克隆化
用HT培养基制备阳性杂交瘤细胞悬液,取样进行台盼兰染色和计数;以HT培养基将杂交瘤细胞稀释至20个/mL和10个/mL,将稀释细胞悬液分别加入96孔培养板,每孔0.1mL,细胞含量分别为2个/孔和1个/孔,置5%CO2 37℃培养,5-7天观察细胞克隆生长情况,选取单克隆生长孔细胞上清,以ELISA检测分泌抗体;对阳性克隆进行连续5次克隆,使其抗体分泌阳性率达95%以上,扩大培养,冻存细胞,获得稳定分泌抗VP4蛋白单克隆抗体的杂交瘤细胞株。其中的3株分别为4C3、6A4和6H8。
实施例4抗VP4蛋白单克隆抗体的制备
用降植烷腹腔注射成年雌性BALB/c小鼠,0.2mL/只,致敏1周后,腹腔注射杂交瘤细胞悬液5×106-1×107,7-10天后采集小鼠腹水,12000g离心3min,收集上清,-70℃冻存,获得单克隆抗体4C3、6A4和6H8腹水6.5-8mL。
实施例5抗VP4蛋白单克隆抗体的腹水效价测定
用PBS缓冲液1000倍稀释抗VP4蛋白单克隆抗体腹水,经倍比稀释后,分别加入VP4重组蛋白(2μg/mL)包被的酶标板,100μL/孔,37℃孵育2h;PBST洗涤3次,加入1∶5000稀释的HRP标记羊抗小鼠IgG抗体,37℃孵育1h,PBST洗涤后,加入显色底物OPD-H2O2,避光反应10min,用2M H2SO4终止反应,用酶标仪读取OD490值,以与阴性OD490值的比值大于2.1判为阳性,以阳性孔的最大稀释度为抗VP4蛋白单克隆抗体腹水效价。结果测得单克隆抗体4C3、6A4和6H8腹水的ELISA效价分别为:6.4×105、2.6×106和5.2×106。
实施例6抗VP4蛋白单克隆抗体与IBDV病毒蛋白的反应性与特异性鉴定
以间接免疫荧光测定抗VP4蛋白单克隆抗体与IBDV病毒蛋白的反应性与特异性。鸡胚成纤维细胞经IBDV感染24h,PBS漂洗两次;加入甲醛∶丙酮=1∶1的固定液,100μL/孔,固定1h;弃固定液,通风干燥;分别加入单克隆抗体4C3、6A4t和6H8的细胞培养上清,100μL/孔,37℃孵育1h;PBS洗涤3次,加入1∶100稀释的FITC标记羊抗小鼠IgG抗体,37℃孵育30min;PBS洗涤后,每孔加入PBS 100μL,荧光显微镜观察并照相。结果单克隆抗体4C3、6A4和6H8均特异识别IBDV感染CEF的病毒蛋白(图3)。
实施例7抗VP4蛋白单克隆抗体的Ig亚型测定
利用SBA公司ClonotypingTM System/HRP亚型测定试剂盒测定抗IBDV VP4蛋白单克隆抗体Ig亚型。结果显示,单克隆抗体4C3、6A4和6H8的重链均为IgG1,轻链为κ。
序列表:
上游引物:
5’CGTCGTCCATGGCCGACAAGGGGTACGAGGTAGTC-3’(下划线为NcoI位点);
下游引物:
5’-CGTCGTCTCGAGCATGGCAAGGTGGTACTGGCGTCC-3’(下划线为XhoI位点)。
Claims (2)
1.一种抗传染性法氏囊病病毒(IBDV)VP4蛋白单克隆抗体,其特征在于:该单克隆抗体是用纯化的IBDV VP4重组蛋白为抗原,通过杂交瘤细胞方法获得的,特异识别IBDV感染细胞中的VP4病毒蛋白的单克隆抗体。
2.如权利要求1所述一种抗传染性法氏囊病病毒(IBDV)VP4蛋白单克隆抗体,其特征在于:IBDV VP4重组蛋白是将IBDV VP4基因克隆于原核表达载体pET-28a,在大肠杆菌BL21(DE3)中诱导表达,分离包涵体,用8M尿素溶解,经镍螯合亲和层析纯化获得的表达蛋白。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100701317A CN101121748B (zh) | 2007-07-20 | 2007-07-20 | 抗传染性法氏囊病病毒vp4蛋白单克隆抗体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100701317A CN101121748B (zh) | 2007-07-20 | 2007-07-20 | 抗传染性法氏囊病病毒vp4蛋白单克隆抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101121748A true CN101121748A (zh) | 2008-02-13 |
CN101121748B CN101121748B (zh) | 2010-07-21 |
Family
ID=39084268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100701317A Expired - Fee Related CN101121748B (zh) | 2007-07-20 | 2007-07-20 | 抗传染性法氏囊病病毒vp4蛋白单克隆抗体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101121748B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101402945B (zh) * | 2008-11-14 | 2010-10-06 | 扬州大学 | 表达抗传染性法氏囊病病毒微小rna重组禽腺联病毒的制备方法 |
CN108484759A (zh) * | 2018-03-01 | 2018-09-04 | 东北农业大学 | 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
CN110373393A (zh) * | 2019-06-06 | 2019-10-25 | 江苏省农业科学院 | 抗传染性法氏囊病毒vp2蛋白的单克隆抗体杂交瘤细胞株1h6 |
-
2007
- 2007-07-20 CN CN2007100701317A patent/CN101121748B/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101402945B (zh) * | 2008-11-14 | 2010-10-06 | 扬州大学 | 表达抗传染性法氏囊病病毒微小rna重组禽腺联病毒的制备方法 |
CN108484759A (zh) * | 2018-03-01 | 2018-09-04 | 东北农业大学 | 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用 |
CN110373393A (zh) * | 2019-06-06 | 2019-10-25 | 江苏省农业科学院 | 抗传染性法氏囊病毒vp2蛋白的单克隆抗体杂交瘤细胞株1h6 |
Also Published As
Publication number | Publication date |
---|---|
CN101121748B (zh) | 2010-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pitcovski et al. | Insect cell-derived VP2 of infectious bursal disease virus confers protection against the disease in chickens | |
CN109536461B (zh) | 一种o型口蹄疫病毒突变株及其制备方法和应用 | |
CN102614507B (zh) | 一种o型口蹄疫分子标记疫苗及其制备方法 | |
Pelosi et al. | The seroepidemiology of genogroup 1 and genogroup 2 Norwalk‐like viruses in Italy | |
CN103539842A (zh) | 草鱼呼肠孤病毒ⅱ型s10基因编码的重组蛋白、由其制备的多克隆抗体及应用 | |
CN110551212A (zh) | 抗gii.4型诺如病毒衣壳蛋白vp1和病毒样颗粒vlp单克隆抗体的制备方法和应用 | |
CN113480642B (zh) | 抗非洲猪瘟病毒CD2v蛋白单克隆抗体、制备方法及应用 | |
CN106866796A (zh) | 草鱼呼肠孤病毒ⅱ型s9基因编码的重组蛋白及其应用 | |
CN101121748B (zh) | 抗传染性法氏囊病病毒vp4蛋白单克隆抗体 | |
CN116042679A (zh) | 一种表达猫杯状病毒VP1蛋白的mRNA疫苗及其制备方法 | |
CN101322844B (zh) | 无病毒非结构蛋白的口蹄疫疫苗及其制备方法 | |
CN102242083B (zh) | 抗新i型鸭肝炎病毒3d蛋白单克隆抗体 | |
CN104744572A (zh) | 禽和猪戊型肝炎病毒共有抗原、单克隆抗体和制备方法及应用 | |
CN102229915B (zh) | Ev71病毒单克隆抗体、杂交瘤细胞株及应用 | |
CN101914499B (zh) | 抗水禽细小病毒vp3蛋白单克隆抗体 | |
Saiz et al. | Antigenic comparison of different foot-and-mouth disease vims types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes | |
CN115894672A (zh) | 一种针对诺如病毒gⅱ基因型vp1蛋白的单克隆抗体及其应用 | |
CN112680421B (zh) | 具有广谱性中和猪流行性腹泻病毒的单克隆抗体及其应用 | |
CN108265079A (zh) | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 | |
CN114410593A (zh) | 一种以麻疹病毒为载体的重组新型冠状病毒疫苗的大规模生产工艺 | |
CN113061585A (zh) | 一种基于CRISPR-Cas9技术的重组血清4型禽腺病毒以及制备方法 | |
CN109589406A (zh) | 一种基于原核表达诺如病毒抗原表位的亚单位疫苗及其制备方法 | |
CN103421745B (zh) | 抗东方马脑炎病毒e2蛋白的单克隆抗体(eeev-6e2)及其识别的b细胞表位和应用 | |
CN117778332A (zh) | 一种检测b组鸡星状病毒的双抗夹心elisa方法 | |
CN116836939B (zh) | 一种抗禽脑脊髓炎病毒单克隆抗体杂交瘤细胞株、单克隆抗体、试剂或试剂盒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100721 Termination date: 20130720 |